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The process by which an animal  is able to elaborate an immune response against 
its own tissues is thought to underlie a number of degenerative disorders.  One system 
which may provide insight into this phenomenon is experimental  myasthenia gravis 
(EMG) 1 (1).  Laboratory  animals  immunized  with  purified  nicotinic  acetylcholine 
receptor (AChR) produce anti-receptor antibodies and often develop myasthenia (2). 
Characteristics  shared  by  human  myasthenics  and  myasthenic  animals  include: 
muscular weakness and flaccid paralysis which is aggravated by exercise and relieved 
by acetylcholinesterase inhibitors, hypersensitivity to curare, low amplitude miniature 
endplate  potentials,  decrementing compound muscle action potentials  in electromy- 
ographs, simplification of the postsynaptic membrane at the neuromuscular junction, 
and the presence of circulating antibodies reactive with autologous AChR (3-6). 
Although  many studies  have detailed  the consequences of anti-AChR  antibodies 
binding  at  the  neuromuscular  junction,  less  attention  has  been  focused  on  the 
mechanisms  regulating  the  induction,  maintenance,  and  suppression  of the  anti- 
AChR immune response. The present investigation describes murine EMG which, in 
principle,  will  permit  these mechanisms  to be examined.  Mice have several  distinct 
advantages over animals previously studied  (rabbit  [1], rat  [7, 8], guinea pig [7], and 
monkey [9]).  The immune system of the mouse is better  characterized  than  that  of 
any other animal,  and the availability  of inbred,  congenic, and recombinant  strains 
permit genetic analysis.  Different functional subclasses of lymphocytes can be distin- 
guished by antisera  against  cell surface antigens.  Finally  methodology exists  for the 
selective manipulation of the mouse immune system. 
Another  advantage  of the  mouse  EMG  system  derives  from  the  availability  of 
several  mouse  muscle cell  lines.  In the  studies  described,  use  is  made of the  mouse 
nonfusing muscle cell line BC3H-1  (10). This cell line is a  rich source of mouse AChR 
(11,  12)  and  is well suited  for use as a  target  tissue  in  in vitro studies  of the  mouse 
anti-AChR immune response. 
Materials and Methods 
Snake  Venom Neurotoxins.  a-neurotoxin  from  the  venom  of the  cobra  Naja  naja kaothia 
(Biologieals  Unlimited)  and  a-bungarotoxin  (aBT)  from  the  venom  of the  krait  Bungarus 
multicinctus (Ross Allen's Reptile Institute. Inc., Silver Springs, Fla.), were purified as previously 
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mM NaNa, 1 mM EDTA, pH 7.0. 
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described (11). a-BT was iodinated to sp act of 1 ×  108 and 109 cpm/nmol by the method of 
Vogel et al. (13). 
Purification of AChRfrorn Torpedo californica.  The electric organs of freshly killed T. californica 
were removed at 4°C, cut into cubes (~1 X 1 in), and quick-frozen on dry ice. The frozen tissue 
were stored at -70°C until needed. In a typical preparation, AChR-rich membranes obtained 
from 600  g of electroplax were  solubilized in Triton X-100 and applied to an c~-neurotoxin 
affinity column in a  manner similar to that previously described  (14). The column was then 
washed sequentially with 500 ml of 10 mM Tris, 100 mM NaCI, 50 p,M phenylmethylsulfonyl 
fluoride, 1 mM NaNa,  1 mM EDTA, pH 7.0 (TXB), 0.5% in Triton X-100; 120 ml TXB, 0.5% 
in Triton X-100, 1 M in NaCI; 120 ml TXB 0.5% in Triton X-100; 120 ml TXB 0.1% in Brij- 
35 (Calbiochem-Behring Corp, American Hoechst Corp., San Diego,  Calif.). AChR was then 
eluted by incubating the column bed with 70 ml of TXB, 0.1% in Brij-35,  1 M  in carbamyl- 
choline for 3 h at 4°C. The first  130 ml of carbamylcholine eluate was collected and dialyzed 
overnight against three changes  (1  liter/change) of TXB, 0.1% in Brij-35,  concentrated by 
ultrafiltration to a final vol of 2 ml, and 500/tl was loaded onto each of four sucrose gradients 
(5-20%  sucrose  in TXB,  0.1% Brij-35,  100  mM  in  carbamylcholine). The  gradients were 
centrifuged in a  swinging bucket rotor  (SW41-Ti, Beckman Instruments, Inc., Spinco Div., 
Palo Alto, Calif.) for 20 h at  125,000 g and fractionated with a bottom punch device (Hoefer 
Scientific Instruments, San Francisco, Calif.). Analogous fractions from each tube were pooled. 
The absorbance at 280 nm of each fraction was measured and the protein-containing  peaks 
were  pooled to give  four fractions corresponding to  varying proportions of monomeric and 
dimeric receptor species. The pooled fractions were then dialyzed against multiple changes of 
phosphate-buffered saline (PBS), 0.1% Brij-35, divided into aliquots, and stored under liquid 
nitrogen until needed. 
Mouse AChRfrom BC3H-1 Cell Line.  The nonfusing muscle cell line BC3H-1 was used as a 
source of mouse AChR (10). Cells were grown in Dulbecco's modified Eagle's medium (DME) 
containing 20% fetal calf serum (FCS), at 37°C in 12% CO2, 88% air. Cells were harvested 9- 
12  d  after  passage  and  solubilized in  PBS  containing 6%  Triton  X-100.  12sI-aBT-AChR 
complexes  were formed by incubating the Triton extract with excess ~25I-aBT (~ 10 pmol 12sI- 
aBT per pmol toxin-binding  sites) for 2 h at 4°C. The mixture was then centrifuged at  12,000 
g for 2 min and the supernates were pooled. Unbound 125I-aBT was separated from 125I-aBT- 
AChR complexes by gel  filtration chromatography on a  Sephadex  G-100  (Pharmacia Fine 
Chemicals Div. of Pharmacia, Inc., Piscataway, N. J.) column (2 x  40 cm) equilibrated with 
PBS,  0.1%  Triton X-100,  1  mM  NAN3. Fractions of 0.5  ml  were  collected  and  fractions 
containing radioactivity and appearing in the void volume were  pooled. Toxin-AChR com- 
plexes were used within 24 h of preparation. 
Mice.  All mice used were females 8-12 wk of age weighing between 20 and 30 g. BALB/cke 
mice were obtained from  a  colony maintained at  The Salk Institute. AKR/Cu mice were 
obtained from Cumberland View Farms (Clinton, Tenn.) C3H/St mice were obtained from 
Strong Laboratories (Del Mar, Calif.). All other mice used were obtained from The Jackson 
Laboratory (Bar Harbor, Maine). 
Immunizations.  Mice  were  immunized with  T.  californica ACbR  emulsified in  complete 
Freund's adjuvant (one part aqueous antigen:two parts adjuvant). The amount of detergent 
(Brij-35)  in the emulsion was kept to a  minimum with the final concentration ranging from 
0.025 to 0.075  mg/ml. In the primary sensitization, 200/~1 of antigen emulsion containing 15 
/~g of T. californica AChR was distributed among six intradermal sites along the back (20 pl/ 
site), the hind footpads (20 #I/footpad), and the base of the tail (40 #1). Mice were boosted 5- 
8 wk after the primary sensitization with 100 pl of antigen emulsion containing 15 pg of AChR. 
The antigen was injected at three intradermal sites along the back (20 pl/site) and at the base 
of the tail  (40 pl).  In most cases  the blood was harvested by tail bleeding 7-14 d  after the 
secondary immunization, depending on the physical status of individual mice. 
Radioimmunoassays.  The binding of antibodies to AChR was measured in a  double-layer 
radioimmunoassay technique similar to that described by Patrick et al. (15) using a  10- to 25- 
125  *  -  old molar excess of  I-aBT-AChR complexes over anttbody. In assays  using T.  californica 
AChR, each tube contained 1 pmol of toxin-receptor complexes (0.25 fig of purified AChR 
protein), whereas  in assays  of mouse AChR, each  tube contained 0.25-0.50 pmol of toxin- 
receptor complexes. 206  EXPERIMENTAL MYASTHENIA GRAVIS:  A  MURINE SYSTEM 
AChR Degradation Assays.  The  rates  of AChR  degradation  in  the  cell line BC3H-1  were 
measured in the presence of mouse anti-AChR sera by a  method similar to that  described by 
Heinemann  et  al.  (16).  The  cells were  incubated  with  10  -s  M  12sI-aBT for  2  h  at  37°C  in 
DME-10% FCS, and then washed four times with fresh medium. The medium in each culture 
was replaced with 1 ml of DME-10% FCS containing 2% immune or preimmune mouse serum 
and the cultures were then incubated at room temperature  (21-23°C) for 1 h in an atmosphere 
of 12% CO2 and 88% air. The vol of the cultures was increased  to 2  ml with DME-10% FCS 
and the cultures were returned to an incubator and maintained at 37°C.  100-/~1 samples of the 
culture medium were removed at various times over an 8- to 10-h period and the radioactivity 
in each  aliquot  was  measured  in a  gamma counter.  After the last  aliquot,  the  radioactivity 
remaining  associated with  the cells in each culture  was  measured  in a  filter assay  (11).  The 
average rate of release of radioactivity into the medium from duplicate cultures was determined 
by linear regression analysis using the method of least squares, assuming a  single exponential 
process. 
Exercise of Mice.  Mice were subjected  to  forced exercise by one or more of the  following 
methods:  (a) repetitive grasping, (b) forced running,  (c) inverted hang, or (d)  free swimming. In 
the repetitive grasp exercise, a  mouse is held by the base of the tail and allowed to grasp  the 
steel meshwork of a cage top with its forepaws. The mouse is pulled by the base of the tail until 
it releases its grip.  The procedure is repeated several times in rapid succession. The grip of a 
myasthenic  animal  weakens  appreciably  after  a  few grasps,  while that  of a  normal  animal 
remains comparatively constant.  The forced running exercise entailed gently chasing a  mouse 
for a distance of up to 4 m with a pencil eraser. Severely myasthenic and moderately myasthenic 
mice  cannot  run  at  all,  whereas  weakly  myasthenic  mice  exhibited  paralysis  and  stopped 
running after 2-3 m. In the inverted hang exercise, a  mouse is allowed to stand  on a  piece of 
heavy steel screening, which is then inverted. A  normal mouse moves freely around the screen 
and  can  maintain  the inverted position,  while myasthenic  mice have  difficulty moving and 
soon fall offthe screen. In the free-swimming exercise, a mouse is placed in a container of water 
filled to a  depth  of ~10 cm and equilibrated  to room temperature.  The mouse is allowed to 
swim  freely  for  2  rain.  A  normal  mouse  swims  freely  without  apparent  fatigue.  Severely 
myasthenic and moderately myasthenic mice can swim only for a  few seconds and have to be 
rescued.  Weakly  myasthenic  mice  can  swim  for  the  entire  2-rain  period;  however,  their 
movements  tend  to  be jerky  and  uncoordinated  and  when  returned  to a  solid  surface  they 
exhibit obvious weakness and paralysis. 
Thermosensitivity Test.  Some mice which did not display behavioral characteristics of EMG 
at room temperature  (21-23°C)  did so after warming under a  heat lamp (air temperature  30- 
35°C)  for  <2  rain.  When  returned  to  room  temperature,  such  animals  exhibited  obvious 
weakness and paralysis. 
Electromyography.  Mice were anesthetized by inhalation of methoxyflurane (Pittman-Moore 
Inc., Washington  Crossing, N. J.) and were restrained  on a  cork dissecting board.  Monopolar 
stimulating and recording electrodes were fashioned from stainless steel dissecting pins. Paired 
stimulating electrodes separated  by -2-3  mm were inserted  intramuscularly  near the sciatic 
notch. Recording electrodes were inserted in the medial compartment of the gastrocnemius and 
near the insertion of the Achilles tendon.  To isolate stimulus artifacts, a  ground electrode was 
placed at a variable position between the stimulus and recording electrodes. Pulses were applied 
with a  square-wave stimulator  (model  SD9,  Grass  Instrument  Co., Quincy,  Mass.).  Electro- 
myographic responses were recorded without additional amplification using a  storage oscillo- 
scope (model R5  103N, Tektronix, Inc., Beaverton, Oreg.). 
Neostigmine Treatment.  Neostigmine bromide (0.0375 mg per kg) was given in the presence of 
atropine sulfate (0.015 mg per kg) by intraperitoneal injection. A  typical mouse weighing 20 g 
received 50/LI of a freshly prepared solution containing 0.015 mg per ml of neostigmine bromide 
and 0.006 mg per ml of atropine sulfate in PBS. 
Curare Sensitivity.  The  LDs0  of curare  was  determined  by  the  method  of Litchfield  and 
Wilcoxin (17).  Dose-response curves were constructed with 5-l0 experimental points using  10 
mice of each strain tested per dosage. The drug was dissolved in PBS and given by intraperi- 
toneal injection. The volume in which the drug was administered was normalized to 5 ~1 per g 
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Results 
The studies below describe humoral immune responses against  T. californica AChR 
in  inbred strains  of mice and  their association with  the development of EMG.  All 
animals  were  immunized  with  monomeric AChR  from  a  single  preparation.  The 
subunit composition of this preparation is similar to that described by Raftery et al. 
(18)  with the or, fl, y, and ~ subunits corresponding to 43,500,  50,000, 60,000, and 
63,500 mol wt, respectively. 
In preliminary studies mice were immunized in  T. californica AChR to determine 
whether or not mice do in fact develop EMG. In one experiment, five BALB/c mice 
were immunized with receptor, and one mouse subsequently developed weakness and 
flaccid paralysis which could be relieved by treatment with neostigmine or eserine. 
When the experiment was repeated with a  group of 20 BALB/c mice, not  a  single 
animal  exhibited  any  signs  of  EMG.  From  these  studies  it  was  clear  that 
although BALB/c mice may develop EMG, the frequency is low. Other inbred strains 
of mice were immunized with AChR to determine if they might be more responsive. 
The  frequency of myasthenia  was  found  to  be  higher  in  C57BL/6  (5  of 5),  and 
SJL/J  (4  of 5)  mice than  in  BALB/c  (1  of 25)  and  or C3H/St  (0  of 5)  mice. To 
explore this apparent difference in susceptibility, a more extensive survey was under- 
taken and assay procedures were developed. 
Characteristics of EMG.  The primary criteria used to distinguish myasthenic from 
nonmyasthenic animals is extreme muscular weakness, flaccid paralysis, and increased 
fatigability which can be relieved by acetylcholinesterase inhibitors. Severely affected 
and  moderately affected mice exhibited obvious weakness  without  forced exercise. 
The posture assumed by moderately myasthenic mice is distinctive and is illustrated 
in Fig.  1 A. There is a drooping of the head, neck, and tail; weakness of the forelimbs 
such that the animal cannot support its body weight, exaggerated arching of the back, 
and sprawled hind limbs. Walking is also abnormal and characteristic of the disorder. 
Mice are  able to use their forelimbs only with  great  difficulty and were propelled 
primarily by their hindlimbs.  After exercise, their movements became progressively 
jerky and tremulous, and in some animals, the hindlimbs also became paralyzed. 
As the condition progressed some animals developed severe paralysis. These animals 
could not right  themselves and could not  propel themselves if righted. They could 
neither eat nor groom and consequently lost weight, had  a  ruffled appearance and 
developed mucous deposits around the eyes. A severely myasthenic mouse is illustrated 
in Fig.  1 C. 
Weakly myasthenic mice appeared normal until stressed by: (a) forced running, (b) 
repetitive graspings, (c) inverted hang, (d) free swimming, or (e) thermosensitivity test. 
Myasthenic mice developed obvious weakness during the course of the stresses and 
assumed  a  posture  similar,  if not  identical,  to  that  illustrated  in  Fig.  1A  upon 
completion of the tests. 
All  animals  which  exhibited  myasthenia  could  be  restored  to  nearly  normal 
behavior by treatment with neostigmine. The drug was administered intraperitoneally 
and began  to affect behavior after ~12  min.  The improvement in muscle strength 
realized is illustrated in Fig.  1 B and D. The animals regain nearly normal posture, 
and typically begin feeding, drinking, and grooming behavior soon after treatment. 
The neostigmine-induced repair of weakness lasts  from 2 to  12 h  depending on the FIG.  1  A, B 
FtG.  1.  Posture of myasthenic mice before and after treatment with neostigmine bromide. These 
animals were  immunized with  15 #g of T.  californica  AChR  and  boosted  45  d  later  with  15 #g 
receptor. (A) Moderately myasthenie C57BL/6J without forced exercise. (B) Same animal as in (A), 
12 min after receiving an intraperitoneal injection of 37.5 #g/kg neostigmine bromide plus 15 #g/kg 
atropine sulfate.  (C)  Severely myasthenic BALB/eke.  (D)  Same mouse as in  (C)  but  6  min after 
receiving neostigmine and atropine as described in (B) above. 
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severity  of  the  paralysis.  In  blind  studies,  attempts  were  made  to  correlate  the 
characteristics of EMG described above with weight loss,  hypoactivity, ruffled coat 
and basal metabolic rate. None of these parameters in and of themselves were found 
to be reliable indicators. 
Studies  were  conducted  to  determine  whether  or  not  myasthenic  mice  exhibit 
electromyographs similar  to  those  seen  in  human  myasthenics.  Compound muscle 
action potentials were evoked by supramaximal stimulation of the sciatic nerve and 
were  recorded  in  the  gastrocnemius.  The  tests  were  complicated  by the  fact  that 
myasthenic  mice  are  more  sensitive  to  anesthesia  (methoxyflurane,  ether,  sodium 
pentobarbit~l)  than normal mice and often died before reliable recordings could be 
obtained.  In addition, considerable difficulty was encountered with movement arti- 
facts; although the frequency of these artifacts can be reduced by restraining straps, 
normal mice were sometimes found which exhibited decrementing responses similar 
to those of myasthenics. To circumvent this difficulty, recordings were made from at 
least  two and sometimes as many as four different  recording electrode positions on 
every animal tested. 
In Fig. 2 are recordings from a myasthenic mouse and a matched, adjuvant control 
mouse. The compound muscle action potentials of the myasthenic mouse decrement 
upon stimulation  at  5  Hz without  prior tetanic stimulation.  The amplitude of the 
fifth pulse is 53% that of the first pulse. There is no decremental response in a matched 
adjuvant control mouse when stimulated at  10 Hz even after prior stimulation at  10 
Hz for 5 s. It can be seen that treatment of the myasthenic mouse with neostigmine 
resulted in progressive repair of the decrement. 
Electromyography alone could not be used as an assay to screen mice for EMG. In 
double blind studies consisting of nine myasthenic mice and seven adjuvant control 
mice, myasthenic mice could not always be distinguished from nonmyasthenic mice. 
Decremental responses were detected  in all  moderately myasthenic mice  (exhibited 
obvious weakness  and  paralysis  without  forced  exercise)  and  such  responses  were 
never seen in adjuvant control mice. Weakly myasthenic mice (paralyzed only after 
exercise),  however, did  not  always  give decremental  responses,  and  in  this respect, 
could not be distinguished from control animals. Although electromyography  did not 
result  in  any  normal  animals  being  classified  as  myasthenic,  they  did  result  in 
myasthenic animals being classified as normals. Thus electromyography of hind leg 
muscles was found to be less reliable than behavioral tests in screening for myasthenia. 
Another characteristic of human myasthenia is hypersensitivity to AChR antago- 
nists.  Studies were conducted to determine if myasthenic mice exhibit similar sensi- 
tivity to such drugs. A curare dosage of 100/.tg  per kg had no effect on normal mice, 
resulted in flaccid paralysis in weakly myasthenic mice, and often proved lethal  for 
myasthenic mice which exhibited  obvious weakness  and paralysis.  Similarly,  myas- 
thenic mice were found to be hypersensitive to lZSI-aBT. Although all normal mice 
tested  (n ~- 34)  could tolerate an intrathoracic dose of 24-40/~g per kg, a  dosage of 
0.5-8/~g per kg was lethal  for 90%  of the myasthenic mice  (n  --  10)  tested.  On the 
basis  of these  studies  and  the  previously  described  studies  of acetylcholinesterase 
inhibitors, it was concluded that myasthenic mice exhibit pharmacological character- 
istics similar to human myasthenics. 
To study the strain dependence of EMG it was necessary to determine whether or 
not the time-course of the primary immune response to AChR differed between mice PHILLIP  W.  BERMAN AND JIM  PATRICK 
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Electromyograms obtained from a moderately myasthenic C57BL/6J mouse and from an 
adjuvant-immunized control C57BL/6J mouse. 30 mice were injected, one-half with adjuvant and 
one-half with adjuvant plus  15 #g T. catifornica receptor.  45 d after the first injection, the control 
mice were re-injected with adjuvant and the experimental mice boosted with adjuvant plus receptor. 
70% of the experimental and none of the control mice developed myasthenic paralysis.  Electromy- 
ograms were taken 17 d after the booster injection; (A) myasthenic mouse; (B-D) myasthenic mouse 
6, 12, and 18 min, respectively, after injection with neostigmine plus atropine; (E) compound muscle 
action potential obtained between records  (C) and (D);  (F) control mouse.  In (A-D) stimuli of 10 
V and .035-ms duration were given at a rate of 5 per s without prior stimulation. The same stimulus 
was used to obtain the record in (E). The record in (F) was obtained with a stimulus of 9 V and 
0.01-ms duration applied at a rate of 5 per s after a conditioning stimulation of 5-s duration at  10 
stimuli per s. 
with high and  low susceptibility  to myasthenia.  The kinetics of the primary  immune 
response  to  T. californica  and  BC3H-!  AChR  was  monitored  in  three strains  of mice: 
BALB/c,  C57BL/6,  and  SJL.  Antibody  titers  were  measured  for  five mice  of each 
strain  at each time point.  In Fig. 3  it can be seen that  the primary response continues 
for  at  least  5  wk  after  the  initial  sensitization  with  maximal  anti-AChR  antibody 
concentration occurring near day 30. After boosting, the antibody concentration rises 
3- to  30-fold over that  at  the peak  of the primary  response.  The  titer against  mouse 
AChR  ranges  between  0.2  and  2%  of that  to  T.  californica  AChR  throughout.  No 
significant difference was found in the kinetics of the primary  immune  response to  T. 
caliJbrnica or mouse AChR  between  the high-susceptibility  strains  C57BL/6  and  SJL 
and  the low-susceptibility strain  BALB/c. 
Having  established  that  mice  immunized  with  T.  californica  AChR  do  develop 212  EXPERIMENTAL MYASTHENIA GRAVIS:  A  MURINE SYSTEM 
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Ftc.  3.  Time-course of the humoral immune response to T. califormca AChR assayed on T. californica 
and  BCaH-1 AChR. Mice from  three strains  were immunized on day 0 with  15 /tg T. californica 
AChR as described  in Materials and Methods. At the indicated times, five mice of each strain were 
bled and the concentration of antibodies reactive with T. californica and BC3H- 1 receptor determined. 
Mice were boosted  between day 40 and 45. The figure shows the mean concentration of antibody 
from the five mice taken  at each time as  function of days  after immunization.  (O)  SjL/j;  (O) 
C57BL/6J; (E]) BALB/cke. 
characteristics  which  closely  resemble  myasthenia  gravis,  the  strain  dependence  of 
EMG  could  be  explored  in  detail.  Mice  from  eight  inbred  strains  were  immunized 
with  T. californica  AChR  and  were scored for the behavioral  characteristics  of EMG. 
The results are indicated in Table I. At least one individual of each strain tested, with 
the exception of SWR,  developed myasthenia.  However, the frequency of myasthenia 
was  much  greater  in  some  strains  than  in  others.  The  strains  C57BL/6,  SJL,  and 
AKR  were high responders  with frequencies between 50 and  70%. Other strains such 
as SWR,  BALB/c, and C3H/He  were low responders with frequencies between 0  and 
15%. Additional studies were undertaken  to determine whether or not animals which 
failed  to  exhibit  weakness  or  flaccid  paralysis  might  exhibit  pharmacological  or PHILLIP  W.  BERMAN AND JIM  PATRICK 
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Strain  H-2  Number tested  Number para-  Frequency ofpa-  Curare LDso 
lyzed  ralysis 
~g/g 
1  A/J  a  15  2  0.13  -- 
2 C57BL/6J*  b  45  32  0.71 *  0.450 
3 BALB/c  d  56  4  0.07  0.445 
4 AKR/cu*  k  10  5  0.50*  0.475 
5 C3H/HeJ  k  35  4  0.11  0.415 
6 DBA/1J  q  15  2  0.13  -- 
7 SWR/J  q  15  0  0  -- 
8 SJL/J*  s  45  29  0.64*  -- 
Eight strains of mice were immunized with T. cahfornica  AChR and boosted with the same antigen 40-45 
d after the primary injections.  The mice were then examined for paralysis using the assays described in 
Materials and Methods. The strains, along with their histocompatibility type, and frequency of paralysis 
are listed above. Nonimmunized mice from the strains indicated were tested for sensitivity to curare. 
LD~0 curves were constructed using 5-10 experimental points per strain using 10 mice per point. 
* We have designated these strains as high-responder strains. 
electrophysiological characteristics of myasthenia. Nonmyasthenic animals from the 
strains A/J (n =  10), SWR (n =- 11), and DBA/1 (n =  8) were tested for hypersensitivity 
to curare. None of the animals tested exhibited paralysis or weakness at  dosages of 
140-180/lg per kg which results in flaccid paralysis or death in myasthenic animals. 
10 nonparalyzed BALB/c mice were additionally tested for electromyographic char- 
acteristics  of  myasthenia,  none  of  these  animals  studied  exhibited  decrementing 
responses. 
Mice  typically  developed  symptoms  of  EMG  7-14  d  after  boosting.  In  high 
responder strains (i.e., C57BL/6 and SJL) several individuals developed weakness and 
paralysis 3-4  wk  after  the  primary sensitization, without  boosting. These  animals 
progressively deteriorated until death. Approximately 90% of the animals that devel- 
oped EMG did so within 15 d after boosting. Unlike rats immunized with T. californica 
AChR  (7),  mice  do  not  appear  to  exhibit  distinct  acute  and  chronic  phases  of 
myasthenia.  In  addition,  sensitization to  T.  californica  AChR  in  the  presence  of 
Bordetella pertussis vaccine did not alter the frequency of myasthenia in BALB/c mice 
(n =  20). 
High- and low-susceptibility strains were examined for characteristics which might 
correlate with susceptibility. Because the immune response to  a  number of defined 
antigens is known to segregate with H-2 alleles (19, 20), EMG might also segregate 
with  particular H-2  haplotypes.  It  can be seen in Table I  that  animals of all H-2 
haplotypes  tested  developed  EMG.  It  was  also  found  that  high  and  low  EMG- 
susceptibility strains can share a given H-2 allele. Thus both AKR and C3H/He mice 
possess  the  H-2  k allele, with  AKR  being a  high-susceptibility strain and C3H/He 
being a  low-susceptibility strain. These studies give no indication that the H-2 locus 
alone determines susceptibility to EMG. 
At  the  simplest  level  there  are  two  alternative explanations to  account  for  the 
differences in susceptibility which we observe. In one case there could be a  difference 
in the anti-AChR immune response between high and low responders. In the second 
case the immune response may be the same but neuromuscular transmission may be 
more  sensitive to  a  reduction  in  receptor  density in  high  responders  than  in  low 214  EXPERIMENTAL  MYASTHENIA  GRAVIS:  A  MURINE  SYSTEM 
601.  A 
5oi. 
40. 
30  .  o 
o 
o 
o 
20  .  ~o 
i  ° 
Oo 
_  oo 
~01 ~ 
~  o 
p- 
5  " 
I 
I 
8  " 
o  o 
oO 
o 
8  o  II 
oo  o 
o  •  8 
0  O  • 
0 
.I 
I 
o 
o 
o 
8 
cb 
*  8 
oo 
eo 
o 
o 
o 
o 
o 
o 
I 
i 
BALBIcC3HIAKRIC57BIISJLI DBA/  A/J  SWR/ 
ke  HeJ  Cu  6J  d  Id  O 
I0 
g, 
0 
m 
. 
P, 
I-- 
1- 
001  o 
o 
I 
o  ° 
o 
o 
o 
o 
o  o 
o  ~  o  o  o 
o 
~  o 
o  o  I  • 
o 
o  o 
o 
°  g 
< 0.001 iooooo 
o 
o 
!  • 
o 
o 
coo  im  eo: 
I  ] 
'  4  o 
o 
•  8  ° 
o 
o  I 
o 
I 
o 
o  I 
°t 
o 
o 
o 
i 
ioo  "~ 
o 
I 
BALB/cC3H/  AKR/C57BI/  SJL  DBA/  A/J  SWR/ 
ke  Hed  Cu  6J  J  IJ  O 
Fro.  4.  Concentration of anti-AChR binding sites reactive with T. californica  and mouse BCaH-1 
AChR.  Each  point  represents  the  slope  of a  line  obtained  when  picomoles  of  receptor-toxin 
complexes precipitated was plotted against microliters of mouse serum added. The slope of each 
binding curve was calculated by linear regression  analysis using five experimentally determined 
points and zero.  (A) titer to T. californica  AChR;  (B) titer to mouse BCaH-1  AChR.  (©) Mice not 
exhibiting weakness or paralysis;  (O)  mice exhibiting weakness or paralysis;  (I)  mice exhibiting 
weakness or paralysis 7 d before or 3 d after boosting. 
responders. One way to address this distinction is to determine  sensitivity to an AChR 
antagonist, such as curare, using nonimmunized  mice. If neuromuscular  transmission 
is more sensitive to a  reduction  in the number  of functional receptors in some strains 
of  mice  than  in  others,  then  there  should  be  a  detectable  difference  in  curare 
sensitivity.  This  possibility  was  tested  by  determining  the  curare  LDs0  curves  for 
strains of mice with high and  low susceptibility to myasthenia.  The  results obtained PHILLIP W.  BERMAN AND JIM  PATRICK  215 
are  indicated  in  Table  I  and  show that  the  LDs0  of the  high-susceptibility strains 
C57BL/6 and AKR did not differ significantly from the LD~o  of the low susceptibility 
strains C3H/He and BALB/c, suggesting that high- and low-susceptibility strains do 
not  differ with  respect  to the  fraction of AChR that  must  remain  active to  insure 
synaptic transmission.  This  result  focused attention  on  the  first  alternative,  that  a 
difference  in  the  anti-AChR  immune  response  might  account  for the  existence  of 
strains of high and low susceptibility. 
We first examined the concentration of antibodies reactive with T. californica AChR 
using a  radioimmunoassay procedure. The results  in  Fig.  4A show that  all animals 
tested  developed high titers  of anti-receptor antibodies.  Some strains  such as  SWR 
possessed  very  high  concentrations  of anti-receptor  antibody  but  did  not  exhibit 
EMG, whereas other strains such as C57BL/6 possessed much lower concentrations 
of anti-receptor antibody and frequently exhibited EMG. Strains such as DBA/1 and 
SJL exhibited intermediate titers; with SJL frequently developing EMG and DBA/1 
rarely developing EMG. Thus, there is no obvious correlation between the concentra- 
tion of serum antibodies reactive with  T. californica  AChR and EMG. 
We next considered whether or not the concentration of serum antibody reactive 
with mouse AChR correlated with myasthenia. Antibody concentrations were again 
measured  using  a  radioimmunoassay technique,  but  in  this  instance  the  cell  line 
BC3H-1 was employed as the source of AChR. The results in Fig. 4B show that the 
immune  response  against  mouse  receptor  differs  markedly  from  that  against  T. 
californica receptor in that the range of titers to the mouse protein spans four orders of 
magnitude, whereas that  to the elasmobranch protein spans less than two orders of 
magnitude. This increased variability is found within a given strain as well as between 
strains. Furthermore, some individuals of all strains tested had high concentrations of 
serum  antibodies  reactive  with  mouse AChR,  but  the  presence of such  antibodies 
does not correlate with myasthenia. 
Again, some animals, such as SWR, were found to possess  very high levels  of anti- 
mouse receptor antibody but gave no indication of EMG. Other animals, particularly 
C57BL/6, possessed low levels  of antibody reactive with autologous AChR but  did 
develop EMG. Thus the presence of antibodies reactive with autologous AChR is not 
sufficient to ensure myasthenia. The finding that animals with very low levels of anti- 
AChR antibody seem to develop EMG which is as severe as that seen in individuals 
with high levels  of anti-AChR antibody suggests that  if indeed humoral antibodies 
are able to induce paralysis, then an antibody subpopulation of a particular structure 
and/or specificity is required. 
We began a search for a correlating specificity by testing whether or not nonmyas- 
thenic mice which possess high concentrations of antibody against autologous AChR 
also make antibodies which react with determinants on the receptor which are exposed 
on the cell surface. This question was answered by measuring the ability of immune 
serum to increase the rate of AChR degradation on cultured muscle cells.  A number 
of studies  have demonstrated  that  antibody binding to AChR on cultured  muscle 
cells results in an increase in the rate of AChR degradation (16, 21, 22). If antibodies 
from nonparalyzed mice increase the rate of AChR degradation they must contain 
populations which react with cell-surface determinants.  Fig. 5 shows that the rates of 
AChR degradation  measured  without  added  mouse serum  and  in  the  presence  of 
adjuvant control mouse serum are identical and correspond to an AChR half-life of 
9.3  h.  The  rate  of AChR  degradation  in  the  presence  of serum  from  a  mouse 216  EXPERIMENTAL  MYASTHENIA  GRAVIS: A  MURINE  SYSTEM 
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FIG. 5.  Effect  of serum from receptor-immunized  and adjuvant-immunized  control mice on the 
rate of degradation of BC3H-1 AChR. Cultures of BCaH-1 were labeled with ]2SI-o~BT,  washed, and 
covered with  1 ml of growth medium containing  10% FCS. Mouse sera were then added to give a 
2% solution and the cultures returned  to the incubator,  and the growth medium  sampled  at the 
times indicated.  (O) control; (0) serum from paralyzed SJL/J; (A) serum from control immunized 
SJL/J. 
immunized  with  72.  californica  AChR  increases  the  rate of AChR  degradation  such 
that  the  receptor  half-life is  reduced  to  3.5  h.  Degradation  rates  measured  in  the 
presence of sera from strains highly susceptible to myasthenia, i.e., C57BL/6 and SJL 
are  indicated in  Table  II.  9  out  of the  11  sera  tested  increased  the  rate  of AChR 
degradation at the single serum concentration  (2%)  tested. The AChR  half-life does 
not strictly correlate with the concentration of anti-receptor antibodies. Thus,  serum 
249 contains the highest concentration of antibodies reactive with mouse AChR  and 
increases the  rate  of receptor degradation  by  a  factor  of  1.6.  Another  serum,  262, 
contains  one-third  the  concentration  of antibody  reactive  with  mouse  AChR,  yet 
increases the rate of degradation by a  factor of 2.7. This result suggests that there are 
either anti-receptor antibody subpopulations which are more effective than others in 
increasing the rate of AChR degradation, or that the concentration of the species that 
increases the rate is higher in 262 than in 249. When sera from mice without detectable 
titers against mouse AChR  were tested, the rates of AChR  degradation remained at 
control values. Serum from nonparalyzed animals with  high concentrations of anti- 
body reactive with  autologous receptor were  tested  for AChR  degradation activity 
and  results  in  Table  I! were  obtained.  8  of the  10  sera  tested  increase  the  rate  of 
AChR  degradation  and  therefore  must  contain  antibodies which  bind  to  exposed 
antigenic  determinants.  By  this  criterion  then,  antibodies  from  paralyzed  animals 
could not be distinguished from nonparalyzed animals. This result demonstrates that 
the presence of antibodies reactive with exposed cell surface antigenic determinants 
on AChR  is not sufficient to result in the induction of myasthenia. Furthermore, the 
presence of antibodies which are capable of increasing the rate of AChR degradation PHILLIP  W.  BERMAN  AND JIM  PATRICK 
TAnLE  II 
Effect of Sets from Immunized and Control Mice on the Degradation Rate of BCaH-I AChR 
217 
Titer to BCsH-1  t~ AChR  t½ control/t½ 
Strain  Mouse  Paralysis  AChR  turnover  anti-AChR 
/LM  h 
1 C57BL/6J  202  +  0.28  7.5  1.23 
2  204  +  0.72  6.2  1.30 
3  210  +  0.88  9.0  1.04 
4  211  +  0.17  9.5  0.93 
5  213  +  0.32  8.3  1.12 
6  215  +  0.16  4.5  2.06 
7  SJL/J  249  +  1.10  5.0  1.62 
8  256  +  0.23  4.3  2.16 
9  260  +  0.64  3.2  2.95 
10  262  +  0.39  3.5  2.69 
11  264  +  0.59  3.5  2.69 
12  BALB/cke  22  --  <0.001  8.8  1.00 
13  24  -  <0.001  8.8  1.00 
14  26  -  <0.001  7.3  1.20 
15  43  -  <0.001  8.3  1.00 
16  A/J  123  -  <0.001  9.1  0.97 
17  124  -  <0.001  9.5  0.93 
18  126  -  <0.001  9.5  0.93 
19  136  -  <0.001  9.5  0.93 
20  137  -  <0.001  9.1  0.97 
21  SWR/J  142  -  <0.00l  8.5  0.94 
22  143  -  <0.001  8.5  0.94 
23  141  -  0.28  9.0  0.89 
24  145  -  1.60  6.9  1.16 
25  146  -  1.90  4.0  2.00 
26  148  -  1.50  3.2  2.50 
27  149  -  0.23  6.1  1.30 
28  C3H/HeJ  59  -  1.60  9.8  0.95 
29  62  -  0.12  5. l  1.82 
30  64  -  0.26  6.0  1.55 
31  65  -  0.10  4.5  2.05 
32  66  -  0.66  4.7  1.72 
Sera from six strains of mice were tested for their ability to increase the rate of degradation of BCaH-1 
AChR. Two high-responder strains (C57BL/6J and SjL/j) and four low-responder strains (BALB/cke, A/ 
J, C3H/HeJ, and SWR/J)  were used. The degradation rates were determined as described in Materials 
and Methods. Each serum was tested at a  concentration of 2% in the presence of 10%  FCS. The results 
from  each  experimental serum  are given relative to  results obtained with serum  from  nonirnmunized 
animals of the same strain. Also included are titers to  mouse BCaH-1  AChR and whether or not  that 
particular animal developed myasthenic paralysis. 
on  cultured  muscle  cells does not  correlate  with  weakness  or flaccid paralysis  charac- 
teristic of myasthenia. 
Another  antigenic  specificity  which  we  considered  concerned  the  possibility  that 
antibodies  elaborated  against  mouse  AChR  but  not  T.  californica  AChR  correlated 218  EXPERIMENTAL MYASTHENIA GRAVIS: A MURINE SYSTEM 
with myasthenia. Such antibodies could only arise as a consequence of an autostim- 
ulatory  immune  response  against  endogenous  AChR.  The  concentration  of serum 
antibody  uniquely  reactive  with  mouse  AChR  was  estimated  by  comparing  the 
binding of anti-receptor sera to mouse ~25I-aBT-AChR complexes alone, and in  the 
presence of a  100-fold excess of unlabeled  T. californica  aBT-AChR complexes. If all 
of the antibody which binds to mouse AChR was actually elicited against antigenic 
determinants on  T.  californica  AChR,  then  1% or less of the mouse  mSI-aBT-AChR 
complexes precipitated in the absence of T. californica AChR should be precipitated in 
the presence of T. californica AChR. If antibodies preferentially bind to mouse AChR 
rather  than  T.  californica  AChR,  then  1%  or  more  of the  mouse  mSI-aBT-AChR 
complexes precipitated in the absence of T. californica AChR should be precipitated in 
the presence of T. californica AChR. 
The results obtained are indicated in Table III. In 60% of the mice tested, all of the 
antibodies reactive with mouse AChR also react with antigenic  determinants on  T. 
californica  AChR.  40% of the animals tested possessed antibodies which appear to be 
directed  against  antigenic  determinants  present  on  mouse  AChR  but  not  on  T. 
californica AChR. In 85% of these mice, the antibody-binding activity unique to mouse 
AChR accounts for 10% or less of the total binding to mouse AChR. The occurrence 
of  antibodies  against  determinants  unique  to  mouse  AChR  does  not  appear  to 
correlate with experimental myasthenia because approximately equal percentages of 
both myasthenic and nonmyasthenic mice possessed antibodies with this specificity. 
Discussion 
Mice from eight inbred strains were immunized with  T. californica AChR. Individ- 
uals  from  all  strains  tested,  with  the  exception  of  SWR,  developed  behavioral, 
electrophysiological,  and  pharmacological  features  of myasthenia  gravis.  The  fre- 
quency of myasthenia-like muscular weakness and flaccid paralysis varied consider- 
ably among strains.  Mice  of the  C57BL/6,  AKR,  and  SJL strains  exhibited  high 
susceptibility  with  50-70%  of the  injected  animals  becoming paralyzed.  All  other 
strains tested exhibited lower susceptibilities with frequencies of myasthenia ranging 
from 0 to 15%. These results suggest that mice from all strains can develop myasthenia, 
but that susceptibility to EMG is a  heritable trait characteristic of some strains and 
not others.  This conclusion is also supported by studies of susceptibility to EMG in 
the F1 offspring from matings of the high-susceptibility strain C57BL/6 with the low 
susceptibility strain BALB/c where Fa hybrids appear to be at least three times more 
susceptible  (95%  confidence  interval)  to  EMG than  the  low susceptibility parental 
type, BALB/cke (P. W. Berman and J. Patrick. Manuscript in preparation.). 
In  these studies,  all  mice immunized  developed  antibody  to  T.  californica  AChR 
(mean concentration:  22.3/~M,  n =  124).  Individuals of all strains tested developed 
serum antibodies reactive with mouse AChR (mean concentration: 0.34 ~M, n =  127). 
The occurrence of antibodies reactive with mouse AChR  did not correlate with the 
myasthenic phenotype in that many individuals were found to possess high concen- 
trations of antibody reactive with autologous AChR, yet were not myasthenic. Other 
mice were found to possess very low concentrations of antibody to autologous AChR 
and exhibited all the features normally associated with myasthenia. The main point 
from these studies is that mice are able to tolerate high concentrations of antibodies 
reactive with autologous AChR without exhibiting paralysis. PHILLIP W.  BERMAN  AND JIM  PATRICK 
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Percentage of Antibody Binding to BC:d-I-I AChR Not Reactive with T. californica AChR 
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Strain  Mouse No.  Titer to BCaH-I AChR  EMG  Percent residual binding 
#M  % 
l  BALB/cke  23  0.54  -  1.2 
2  27  0.25  --  <0.5 
3  30  0.47  -  "<0.5 
4  39  0.36  -  <0.5 
5  C3H/HeJ  52  0.42  --  I.I 
6  59  1.6O  -  <0.5 
7  62  0.12  --  <0.5 
8  63  0.11  +  <0.5 
9  64  0.26  -  <0.5 
10  DBA/IJ  101  0.02  -  22.6 
11  104  0.08  -  8.0 
12  112  0.15  --  <0.5 
13  SWR/J  145  1.06  <0.5 
14  146  1.08  1.0 
15  147  0.26  12.6 
16  148  1.40  17.6 
17  150  0.24  3.7 
18  151  1.40  --  "<0.5 
19  152  0.73  --  1.5 
20  C57BL/6J  202  0.28  +  1.0 
21  203  0.30  --  8.9 
22  204  0.72  +  3.1 
23  205  0.16  --  4.8 
24  210  0.88  +  4.9 
25  211  0.17  +  <0.5 
26  213  0.32  +  1.0 
27  215  0.16  +  3.4 
28  216  0.27  --  4.2 
29  SJL/J  247  0.32  +  2.7 
30  249  1.10  +  <0.5 
31  254  0.61  -  0.7 
32  255  0.28  -  20.3 
33  256  0.23  +  2.9 
34  257  0.26  -  1.3 
35  258  0.24  +  5.0 
36  259  0.24  +  <0.5 
37  260  0.64  +  1.0 
38  261  2.00  +  0.8 
39  262  0.39  +  <0.5 
40  263  0.34  -  3.4 
41  264  0.59  +  <0.5 
Competitive binding of anti-AChR antibodies to T. califomica receptor and receptor from the mouse muscle cell line BCaH- 
1. For each serum, antibody binding to BC3H-I receptorJZ%aBT complexes was determined in the presence and absence 
of a  100-fold  molar excess  of unlabeled  T. califomica  receptor-aBT complexes. If all  the antibodies reactive with BC3H-I 
receptor are equally reactive with T  californica  receptor, then the binding to BCzH-I receptor-X~I-aBT complexes in the 
presence of 7] californica  receptor-aBT complexes should be reduced to 1% of the value determined in the absence of the T 
callfornica  protein. This value is indicated on the column on the far right as the percent residual binding. A residual binding 
value >1% indicates that the antibodies have a  higher affinity for the BCaH- 1 receptor than the "F ca/ifornica  receptor. Also 
indicated are the mice which developed paralysis after immunization. 
Two alternative explanations could account for the lack of correspondence between 
the concentration  of anti-AChR  antibodies  and paralysis.  One possibility  is that  the 
immune response to AChR differs between myasthenic and nonmyasthenic mice. The 
other possibility  is that  there is no difference  in response to AChR but that  there is a 220  EXPERIMENTAL MYASTHENIA GRAVIS: A MURINE SYSTEM 
difference in  the  neuromuscular junction.  The latter possibility seems unlikely.  No 
difference in curare sensitivity could be detected between high- and low-susceptibility 
strains,  suggesting that  there  is no great disparity in  the numbers of AChR  which 
must be blocked to impair neuromuscular transmission. In addition, antibody reactive 
with autologous AChR  is often found in nonparalyzed individuals of strains highly 
susceptible to myasthenia. If there is no difference in the anti-AChR immune response, 
then  this  finding  could  only  be  explained  by  polymorphism  in  neuromuscular 
transmission within an isogenic strain; this possibility also seems unlikely. 
A  difference  in  the  anti-AChR  immune  response  between  myasthenic  and  non- 
myasthenic animals appears to be a  more tenable hypothesis. The simplest interpre- 
tation  would  be that  an  antibody  subpopulation  of a  particular  structure  and/or 
specificity is required  for the induction  of paralysis in mice. Because mice with very 
low concentrations of anti-AChR antibody were paralyzed, large free concentrations 
of the particular antibodies are not required.  The occurrence of high concentrations 
of anti-AChR antibody might be because the mice were immunized with solubilized 
receptor.  AChR  is  an integral  membrane protein  and  a  considerable  portion of its 
structure may be hidden  by the plasma membrane. It would be expected that  mice 
make  antibodies  against  antigenic  determinants  on  solubilized  AChR  which  are 
sequestered, in situ.  Such antibodies could yield significant titers in radioimmunoas- 
says, but would not be expected to bind receptor in vivo. 
The possibility that  myasthenia  might  correlate with  the  presence of antibodies 
reactive with antigenic determinants on AChR which are exposed on the cell surface 
was considered. Both paralyzed and nonparalyzed mice made antibodies which bind 
to cell surface determinants and increase the rate of AChR degradation.  This result 
demonstrates that the presence of antibodies reactive with autologous AChR in situ is 
not sufficient to insure paralysis; which again suggests that an anti-receptor subpop- 
ulation of a particular structure and specificity is required. It has been suggested that 
antibody-induced  AChR  degradation  at  the  neuromuscular junction  might  be  a 
major  pathological  mechanism  in  myasthenia  gravis  (23-25).  In  these  studies  we 
found  that  both  paralyzed and  nonparalyzed  mice possessed antibodies  which  can 
increase the rate of AChR degradation on cultured muscle cells.  This result does not 
rule  out  the  role of antibody-induced  AChR  degradation  in  myasthenia  gravis.  It 
should be noted that the AChR present on cultured muscle cells is of the extrajunc- 
tional type. The electrophysiological, metabolic, and biochemical, properties of extra- 
junctional  AChR  are known  to differ from those of junctional  AChR  (26,  27)  and 
recent  studies  suggest  that  there  is  an  immunological  difference between  the  two 
receptor types (28).  It is not known whether antibody from nonparalyzed mice which 
accelerates the rate of extrajunctional  AChR degradation can similarly increase the 
rate of  junctional AChR degradation. Studies are, however, in progress to resolve this 
question  (P. W. Berman and S. Heinemann. Unpublished results.). 
Immunization  of mice  with  T.  californica  AChR  can  result  in  the  formation  of 
antibodies  against  antigenic  determinants  present  on solubilized  mouse AChR  but 
not solubilized T. californica receptor. Such antibodies can only arise as a consequence 
of an immune response stimulated by endogenous receptor. Because such antibodies 
were found in myasthenic and nonmyasthenic animals alike, they do not appear to 
play a  dominant  role in  the expression of the  myasthenic phenotype.  It is  possible 
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strains  and not others.  Further studies employing more animals will be required  to 
resolve this point. 
Previous  attempts  to  induce  EMG  in  mice  with  T.  californica  AChR  yielded 
equivocal  results.  Fulpius  et  al.  (29)  repeatedly  immunized  BALB/c, DBA/2,  and 
NZB mice with receptor and found that although the mice made high levels  of anti- 
AChR antibody, they did not develop EMG.  Fuchs et  al.  (30),  on the other hand, 
reported that mice immunized with  T. californica  AChR did develop EMG and that 
the response was strain dependent in that AKR mice seemed to be very susceptible to 
EMG, and other strains, particularly those possessing the H-2  q and H-2  s haplotypes, 
seemed to be resistant to EMG. Our studies are compatible with the results of Fulpius 
et  al.  (29) in  that  BALB/c mice appear to be a  low EMG-susceptibility strain  and 
exhibit a high serum concentration of anti-AChR antibodies. Our studies are consist- 
ent with those of Fuchs et al.  (30)  to the extent that susceptibility to EMG is strain 
dependent, but differ in that mice possessing the H-2  q and H-2  s haplotypes were not 
found to be  resistant  to the induction of EMG.  On  the contrary, SJL mice which 
possess the H-2  s haplotype appear to be a  high-susceptibility strain. The observation 
that  a  high-susceptibility strain  (AKR)  and  a  low-susceptibility strain  (C3H/HeJ) 
possess  the  same  H-2  allele  (H-2k),  suggests  that  H-2  haplotype  alone  does  not 
determine susceptibility or resistance to myasthenia. 
In  conclusion,  immunization  of mice  with  AChR  can  result  in  paralysis.  The 
probability with which any given mouse can be expected to become paralyzed can be 
estimated  knowing  the  strain  of  the  mouse  but  not  by  knowing  its  haplotype. 
Knowledge of the concentration of circulating antibodies directed against T. californica 
or  mouse  receptor  does  not  allow  an  estimation  of the  probability  of paralysis. 
Furthermore, animals containing antibodies which increase the rate of extrajunctional 
AChR degradation are not always paralyzed. These observations, plus the observation 
that the susceptibility to paralysis can be manipulated genetically (i.e.,  the use of F~ 
hybrids), make the mouse system of myasthenia attractive from two points of view. 
On one hand it may identify the immunological mechanism that results in paralysis. 
In  addition  it  may provide access  to  those  elements  of the  immune system  which 
malfunction during the initiation of an anti-self immune response. 
Summary 
Mice from eight inbred strains were immunized with acetylcholine receptor (AChR) 
purified  from  Torpedo  californica.  All  mice  developed  high  concentrations of serum 
antibodies (10-6 M) against the immunogen and ~80% possessed antibodies reactive 
with  mouse  nicotinic  AChR.  33%  of the  mice  immunized  (n  =  236)  developed 
muscular weakness and flaccid paralysis. Behavioral, electrophysiological, and phar- 
macological similarities  were  found  between  the  experimentally  induced  muscular 
weakness  and  the  disease  myasthenia  gravis.  Susceptibility  to  experimental  myas- 
thenia was found to be strain dependent in that the frequency of paralysis was much 
greater in some strains than others. The occurrence of muscular weakness and flaccid 
paralysis  did  not  correlate  with  the  concentration  of antibodies  reactive  with  T. 
californica  or mouse AChR. Anti-receptor antibodies which increased the rate of AChR 
degradation on the mouse muscle cell line, BC3H-1, were found in the serum of both 
myasthenic and  nonmyasthenic mice.  40%  of the  mice  tested  possessed  antibodies 
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receptor.  The occurrence of antibodies  unique  to mouse  receptor  did  not  correlate 
with myasthenia.  Thus,  myasthenia in the mouse does not occur simply as a  conse- 
quence of the presence of antibodies  directed against  cell surface antigenic  determi- 
nants  of AChR.  If anti-AChR  antibodies  are  both  necessary and  sufficient  for the 
induction of myasthenia,  then  these studies suggest that populations of a  particular 
structure  and/or specificity are  required.  It  is  anticipated  that  the  mouse model of 
myasthenia gravis will permit the regulation of the anti-receptor immune response to 
be studied in detail. 
Received  for publication 27 August  1979. 
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